Mitochondria are the power stations of cells that convert food and oxygen into energy. Mitochondrial diseases occur when mitochondria cannot produce enough energy, causing organ systems to fail. There is no cure for mitochondrial disease currently, but treatment focuses on relieving symptoms and improving energy production through supplements and diet. Gene therapy shows promise for treating mitochondrial diseases by replacing mutated genes, though challenges remain due to mitochondria's unique biology. Clinical trials so far show gene therapy can improve vision in some patients with Leber's hereditary optic neuropathy.
Mitochondria are the power stations of cells that convert food and oxygen into energy. Mitochondrial diseases occur when mitochondria cannot produce enough energy, causing organ systems to fail. There is no cure for mitochondrial disease currently, but treatment focuses on relieving symptoms and improving energy production through supplements and diet. Gene therapy shows promise for treating mitochondrial diseases by replacing mutated genes, though challenges remain due to mitochondria's unique biology. Clinical trials so far show gene therapy can improve vision in some patients with Leber's hereditary optic neuropathy.
Mitochondria are the power stations of cells that convert food and oxygen into energy. Mitochondrial diseases occur when mitochondria cannot produce enough energy, causing organ systems to fail. There is no cure for mitochondrial disease currently, but treatment focuses on relieving symptoms and improving energy production through supplements and diet. Gene therapy shows promise for treating mitochondrial diseases by replacing mutated genes, though challenges remain due to mitochondria's unique biology. Clinical trials so far show gene therapy can improve vision in some patients with Leber's hereditary optic neuropathy.
Mitochondria are the power stations of cells that convert food and oxygen into energy. Mitochondrial diseases occur when mitochondria cannot produce enough energy, causing organ systems to fail. There is no cure for mitochondrial disease currently, but treatment focuses on relieving symptoms and improving energy production through supplements and diet. Gene therapy shows promise for treating mitochondrial diseases by replacing mutated genes, though challenges remain due to mitochondria's unique biology. Clinical trials so far show gene therapy can improve vision in some patients with Leber's hereditary optic neuropathy.
Download as DOCX, PDF, TXT or read online from Scribd
Download as docx, pdf, or txt
You are on page 1of 4
What Are Mitochondria?
Mitochondria are the “energy factory” of our body. Several thousand
mitochondria are in nearly every cell in the body. Their job is to process oxygen and convert substances from the foods we eat into energy. They are like power stations, supplying the energy our cells need to function. Mitochondria produce 90% of the energy our body need. Cells make up tissues and organs in our bodies, for example the heart and liver. If our cells do not have enough energy, the tissues or organs do not work properly. In much the same way, if power stations do not produce enough energy there will be areas of blackout, where parts of the country cannot function. What are mitochondrial diseases? When mitochondria cannot convert food and oxygen into life-sustaining energy, cell injury and even cell death follow. When this process is repeated throughout the body, organ systems begin to fail and even stop functioning. Mitochondrial diseases can be present at birth but can also occur at any age. Mitochondrial diseases can affect almost any part of the body, including the cells of the brain, nerves, muscles, kidneys, heart, liver, eyes, ears or pancreas. Mitochondrial dysfunction occurs when the mitochondria don't work as well as they should due to another disease or condition. Many conditions can lead to secondary mitochondrial dysfunction and affect other diseases, including: -Alzheimer’s disease. -Muscular dystrophy. -Lou Gehrig’s disease. -Diabetes. -Cancer. The parts of the body commonly affected are those that have the highest energy demands, such as brain, muscle, liver, heart and kidney. When these systems are effected Mitochondrial Disease is usually progressive. Treatments? Unfortunately, there is no cure for Mitochondrial Disease at present. Treatment is usually supportive, relieving the symptoms that can develop, for example, treating seizures with medication. Doctors can also try to make energy production more efficient, using co-factors and vitamins. Examples of these are Ubiquinone (Coenzyme Q10), Thiamine and Riboflavin. Some people find that using a special diet can help and this varies depending on which part of the energy production process is affected. However, this should only be tried with guidance from your metabolic team. Gene therapy for mitochondrial diseases. The recent success of gene therapy across multiple clinical trials has inspired a great deal of hope regarding the treatment of previously intractable genetic diseases. This optimism has been extended to the prospect of gene therapy for mitochondrial disorders, which are not only particularly severe but also difficult to treat. However, this hope must be tempered by the reality of the mitochondrial organelle, which possesses specific biological properties that complicate genetic manipulation. In this perspective, we will discuss some of these complicating factors, including the unique pathways used to express and import mitochondrial proteins. We will also present some ways in which these challenges can be overcome by genetic manipulation strategies tailored specifically for mitochondrial diseases. Despite this remarkable progress, gene therapy for inherited mitochondrial disorders may present a unique and fascinating set of challenges that are not fully appreciated by those less acquainted with mitochondrial biology. Mitochondria are, of course, integral to the functioning of the cell, producing the bulk of the energy (in the form of ATP) needed by the cell through the process of oxidative phosphorylation (OXPHOS). The consequences of mutations in the mitochondrial genome (mtDNA) and mitochondria-related nuclear genes are often severe, and the prognosis of such a patient is usually quite poor. Thus, the value in being able to correct such genetic defects in patients is readily apparent. Gene therapy and CRISPR gene editing provide a great deal of promise in the field of medical genetics but have certain limitations in the treatment of mitochondrial diseases that must be addressed if they are to be employed successfully in this context. In the present review, we hope to address this issue by discussing ongoing clinical trials in the use of gene therapy and gene editing technologies to treat genetic diseases, with a particular focus on specific challenges in the use of such approaches for treating mitochondrial diseases. Gene replacement therapy based around the AAV2 vector has shown modest, but promising, success in mice for a variety of nuclear-encoded mitochondrial disease genes. However, the only primary mitochondrial disease currently involved in active clinical trials of gene replacement therapy is Leber’s hereditary optic neuropathy (LHON), caused by mutations in the mitochondrially-encoded MT-ND4 gene. Multiple trials are currently investigating the treatment of LHON using AAV2 vectors and MT-ND4 coding sequences modified to carry an MTS. In general, these trials have produced some improvements in visual function for patients suffering from LHON, particularly in those with a disease course shorter than 2 years prior to the time of treatment. However, it has been noted in at least one of the trials (NCT02652780) that injection of the viral vector into one eye also restored function in the uninjected eye. A qPCR-based analysis appeared to explain this result by showing that the viral vector could be detected in tissues extract from both the injected as well as the uninjected eye. This may suggest that viral vector was transferred from the injected to the uninjected eye via the optic nerves at the optic chiasm, although this mechanism has yet to be fully confirmed. Overall, however, the results of these trials have been generally encouraging, and there is reason to believe that other mitochondrial disease genes may be similarly amenable to gene replacement therapy, so long as protein import and expression level issues are properly addressed. Thus far, very few clinical trials have been conducted with nDNA-related mitochondrial diseases.
Revolutionary Therapies: Unleashing the Potential of Pharmaceutical Biotechnology through Recombinant Methods (Pharmaceutical Biotechnology: Therapies Developed through Recombinant Methods 2)